GILD vs GSK
Gilead Sciences and GSK plc, both Healthcare
Gilead Sciences is the larger company at $154B against $104B. Over the past year GILD returned +36% against +17% for GSK. The RyuScore puts GSK ahead, 67 against 44 out of 100.
| Figure | GILD | GSK |
|---|---|---|
| Last close | $151 | $46.51 |
| Market cap | $154B | $104B |
| Dividend yield | 2.1% | n/a |
| 1-year return | +36% | +17% |
| 5-year return | +155% | +43% |
| RyuScoresector-relative, 1–10 | 44/100 | 67/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Gilead Sciences
Revenue of $7.8B in Q2 2026, net income null. Its largest reported line is HIV Product Sales, 55% of the disclosed total.
GSK plc
Open these two in the interactive comparison to add more names, change the period or see the correlation.